Related Experiment Video
Updated: Jul 6, 2025
08:33
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
Published on: January 5, 2024
1.2K
Double-blind, randomized, placebo-controlled study to evaluate erenumab-specific central effects: an fMRI study
Hauke Basedau1, Kuan-Po Peng1, Marlene Schellong1
1Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf Martinistr. 52, 20246, Hamburg, Germany.
The Journal of Headache and Pain
|January 9, 2024
Summary
Erenumab demonstrated central effects in migraine patients, modulating brain activity in areas like the thalamus. Further research is needed to understand if these effects are direct or secondary to its peripheral action.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Neurology
Background:
- Erenumab is a calcitonin gene-related peptide receptor antagonist used for migraine prevention.
- Previous studies suggest erenumab may have central nervous system effects.
- The precise mechanism of erenumab's efficacy, particularly its central actions, requires further investigation.
Purpose of the Study:
- To rigorously evaluate the central effects of erenumab in migraine patients using a placebo-controlled, double-blind, randomized design.
- To determine if observed changes in brain activity are directly attributable to erenumab treatment.
- To investigate the impact of erenumab on neural pathways involved in migraine pathophysiology.
Main Methods:
- A double-blind, placebo-controlled study involving 44 migraine patients randomly assigned to erenumab 70 mg or placebo.
- Functional magnetic resonance imaging (fMRI) was performed on 40 patients before and four weeks after treatment using a trigeminal nociceptive paradigm.
- Headache diaries were maintained for two months to assess clinical response, defined as a ≥30% reduction in headache frequency.
Main Results:
- A clinical response was observed in 33.33% of the erenumab group and 21.05% of the placebo group.
- fMRI data revealed an interaction between erenumab and treatment response.
- Variance-weighted analysis indicated decreased activity in the thalamus, operculum, and putamen in response to erenumab, suggesting central modulation.
Conclusions:
- The study reproduced central effects of erenumab in a placebo-controlled design, supporting its role in migraine modulation.
- The findings suggest erenumab directly impacts central nervous system activity, although the exact mechanism (direct vs. secondary to peripheral action) warrants further exploration.
- The observed response rate was lower than anticipated, limiting subgroup analyses and highlighting the need for larger sample sizes in future studies.
